CLRB Stock Analysis: Buy, Sell, or Hold?
CLRB - Cellectar Biosciences INC NEW
$3.15
-0.07 (-2.17%)
▼
5d:
-11.02%
30d:
+6.78%
90d:
-3.37%
WAIT
LOW Confidence
Last Updated: February 2, 2026
Earnings: Mar 12, 2026
Get Alerted When CLRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CLRB this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CLRB is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CLRB is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLRB is currently trading at $3.15, which is considered slightly low relative to its 30-day fair value range of $2.99 to $3.74.
Technical Outlook: Technically, CLRB is in a strong downtrend. The price is currently testing key support at $3.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $47.00 (+1392.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLRB is in a strong downtrend. The price is currently testing key support at $3.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $47.00 (+1392.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$2.99 -
$3.74
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1392.1% below Wall St target ($47.00)
- WARNING: Recommendation downgraded due to -11.0% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.99 -
$3.74
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.10
Resistance Level
$3.98
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.42
Wall Street Target
$47.00
(+1392.1%)
Last updated: February 02, 2026 7:38 PM ET
Data refreshes hourly during market hours. Next update: 8:38 PM
Data refreshes hourly during market hours. Next update: 8:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 60 HOLD |
